Medication vs Surgery for Heart Disease: How to Decide

Research-informed explainer — last updated April 12, 2026

Whether medication or surgery is right for your heart disease depends less on which is "better" in the abstract and more on the type and severity of your disease, your symptoms, and what major clinical trials show for patients like you. For stable coronary artery disease, decades of evidence show that medication alone controls symptoms and prevents heart attacks as well as stenting or bypass surgery in most patients — but for emergencies like heart attacks and for certain high-risk anatomies, intervention saves lives that medication alone cannot.

This explainer draws on peer-reviewed work from three cardiologists in the Convene directory: Deepak Bhatt at Mount Sinai, who led major trials on medical therapy and cardiovascular risk reduction; Steven Nissen at the Cleveland Clinic, who has long challenged overreliance on anatomy-guided procedures; and Allan Jaffe at Mayo Clinic, whose work on AHA/ACC guidelines defines the standard of care for acute coronary syndromes.

What's the difference?

"Heart disease" covers a wide spectrum. Most of the medication-versus-surgery debate centers on coronary artery disease (CAD) — the buildup of fatty plaques inside the arteries that supply the heart muscle. Over time these plaques narrow the artery (stenosis) or rupture and cause clots.

Medications address this problem systemically. Statins slow plaque growth and stabilize existing plaques so they are less likely to rupture. Blood thinners (aspirin, P2Y12 inhibitors like clopidogrel, and newer agents) reduce clotting. Beta-blockers lower heart rate and blood pressure, reducing the heart's oxygen demand. ACE inhibitors protect the heart muscle over time. Newer agents like icosapent ethyl (a purified fish oil) have shown meaningful reductions in cardiovascular events on top of statin therapy [3].

Surgery and procedures address the anatomical blockage directly. Percutaneous coronary intervention (PCI), commonly called stenting, threads a balloon-tipped catheter to the blockage, expands it, and leaves a metal mesh stent to keep the artery open. Coronary artery bypass grafting (CABG) uses a vessel harvested from the leg or chest to reroute blood flow around the blockage. Both restore blood flow immediately but do not treat the underlying disease process.

At a glance

When medication is the right first choice

For stable coronary artery disease — meaning you have blockages detected on imaging but your main symptoms are predictable chest pain during exertion (stable angina), not a heart attack — major clinical trials have consistently shown that optimal medical therapy (OMT) produces outcomes equivalent to stenting.

The COURAGE trial enrolled over 2,200 patients with stable CAD and found that adding PCI to OMT did not reduce death or heart attack rates compared to OMT alone over 4.6 years. The ISCHEMIA trial, which enrolled over 5,000 patients with moderate-to-severe ischemia on stress testing, confirmed this: an initial invasive strategy did not improve survival or reduce heart attacks compared to medical therapy alone at five years.

Steven Nissen published an influential piece in 1995 pointing out exactly why these results were predictable: what cardiologists call "luminology" — focusing on the visual appearance of a narrowed artery on an angiogram — tells you relatively little about which plaques are dangerous. Most heart attacks are caused not by the tightest blockages (which often have stable fibrous caps) but by smaller, vulnerable plaques that rupture [7]. Opening a 70% blockage with a stent does not touch those rupture-prone plaques — only systemic therapy does [7].

Medication is also the better choice when:

• Your symptoms are controlled or minimal
• You have multiple small blockages scattered throughout the coronary tree rather than one or two discrete obstructions
• You have significant comorbidities that raise procedural risk
• Your blockage involves a vessel where stenting outcomes are less durable (small vessel, long segment)

When intervention is necessary

Revascularization is not optional in several situations:

Acute heart attack (STEMI or high-risk NSTEMI). When a plaque ruptures and completely blocks a coronary artery, every minute without restored blood flow destroys heart muscle. Emergency PCI — opening the blockage with a balloon and stent, ideally within 90 minutes of arrival — is the standard of care. This is not a medication-versus-surgery decision; it is a medical emergency where catheterization is life-saving. The AHA/ACC guideline for non-ST-elevation acute coronary syndromes (NSTEMI), co-authored by Allan Jaffe, provides the evidence base for which NSTEMI patients need urgent versus early invasive management [8].

Left main disease. Blockage in the left main coronary artery — which supplies the largest territory of heart muscle — significantly increases mortality risk. Both PCI and CABG improve survival over medical therapy in this setting, with CABG preferred for most patients with left main disease and multi-vessel involvement.

Three-vessel disease with reduced heart function. When all three major coronary arteries are significantly blocked and the left ventricle's pumping function is reduced, CABG improves survival compared to PCI or medication alone. This is one of the clearest surgical indications in all of cardiology.

Refractory symptoms. If stable angina persists despite maximally tolerated medications — including a statin, aspirin, a beta-blocker, and a long-acting nitrate — PCI or CABG for symptom relief is a reasonable option even when the survival benefit is uncertain.

What the trials show about medication and cardiovascular risk

One of the most striking additions to the medical therapy toolkit came from the REDUCE-IT trial, led by Deepak Bhatt. Among patients with established cardiovascular disease or diabetes who already had elevated triglycerides despite statin therapy, adding icosapent ethyl (2 g twice daily) reduced the composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, revascularization, and unstable angina by 25% compared to placebo [3]. This is a medication that, on top of statin therapy, produced a reduction in hard cardiovascular events comparable in magnitude to what most revascularization trials show for stable patients.

The SAVOR-TIMI 53 trial, in which Bhatt participated, tested whether adding the diabetes drug saxagliptin to standard therapy would further reduce cardiovascular events in high-risk patients with type 2 diabetes. It did not reduce ischemic events, and it slightly increased hospitalizations for heart failure [2]. This is a reminder that adding more pharmacological treatment to an already-treated patient does not always help, and can sometimes cause harm.

Nissen's landmark 2007 meta-analysis of rosiglitazone — another diabetes drug — found that it was associated with a significant increase in myocardial infarction risk [5], eventually leading to restrictions on its use. A parallel meta-analysis of pioglitazone showed the opposite pattern: reduced risk of death, MI, and stroke, though with a significant increase in heart failure [6]. These studies underscore that the cardiovascular safety of any drug — or any procedure — must be established in trials, not assumed.

What's changing in this field

The major trend is toward more intensive medical therapy rather than more procedures for stable disease. Newer drug classes have expanded what OMT can achieve:

• SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death and heart failure hospitalizations in patients with established heart disease
• GLP-1 agonists (semaglutide, liraglutide) reduce major cardiovascular events in patients with obesity and cardiovascular disease
• PCSK9 inhibitors (evolocumab, alirocumab) lower LDL cholesterol to very low levels and reduce cardiovascular events in high-risk patients who cannot achieve sufficient LDL reduction with statins alone
• Icosapent ethyl provides additional risk reduction in patients with residual triglyceride elevation on statins [3]

At the same time, PCI techniques have improved with drug-eluting stents (which dramatically reduced restenosis compared to bare-metal stents), intravascular imaging guidance, and fractional flow reserve (FFR) assessment — a pressure wire that measures whether a given blockage is actually restricting blood flow enough to cause ischemia, helping cardiologists avoid stenting blockages that look severe on angiography but are not functionally significant.

The net effect: both sides of this debate have gotten better, which is why the decision requires an individualized conversation about your specific anatomy, symptoms, and risk factors.

Questions to ask your cardiologist

• Is my coronary artery disease stable, or is there any sign that my plaques are unstable or at high risk of rupture?
• Have I been on optimal medical therapy — the right doses of a statin, aspirin or another antiplatelet drug, and a beta-blocker — long enough to know whether it controls my symptoms?
• If you recommend a stress test or angiogram, would those results change the treatment plan, or am I already a good candidate for continued medical therapy regardless of what you find?
• If I have a blockage, does the location and type (left main, multi-vessel, single vessel) change whether medication, stenting, or bypass is most appropriate for me?
• Does my heart's pumping function influence the decision? If my ejection fraction is reduced, does that shift the recommendation?
• What is the procedural risk of stenting or bypass for someone with my other health conditions?
• If I choose to continue medical therapy, how will we track whether it is working and know when it is time to reassess?

The bottom line

For most people with stable coronary artery disease and manageable symptoms, medication — optimized and taken consistently — is as effective at preventing heart attacks and death as routine stenting. The anatomical picture on a scan or angiogram is not a reliable guide to who needs a procedure; the physiology (whether blood flow is actually restricted) and the clinical picture (symptoms, heart function, anatomy type) matter far more. Heart attacks, high-risk anatomies like left main disease, and symptoms that persist despite maximally tolerated medication are the clearest indications for intervention. Outside those situations, adding drugs that target triglycerides [3], LDL, blood pressure, and blood sugar is where the evidence for incremental benefit is strongest. The question to bring to your cardiologist is not "do I need surgery?" but "what does my specific pattern of disease actually call for?"